Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586

+ Details

Name:	us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development and sales milestone payments

+ References

No definition available.

+ Details

Name:	vtrs_Developmentandsalesmilestonepayments
Namespace Prefix:	vtrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Divestiture of Business, Deferred Cash Consideration.

+ References

No definition available.

+ Details

Name:	vtrs_DivestitureOfBusinessDeferredCashConsideration
Namespace Prefix:	vtrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Divestiture Of Business, Percentage Ownership In Combined Company After Transaction

+ References

No definition available.

+ Details

Name:	vtrs_DivestitureOfBusinessPercentageOwnershipInCombinedCompanyAfterTransaction
Namespace Prefix:	vtrs_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Divestiture Of Business, Transition Services Agreement, Term

+ References

No definition available.

+ Details

Name:	vtrs_DivestitureOfBusinessTransitionServicesAgreementTerm
Namespace Prefix:	vtrs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Insulin Analog Products

+ References

No definition available.

+ Details

Name:	vtrs_InsulinAnalogProducts
Namespace Prefix:	vtrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of drugs

+ References

No definition available.

+ Details

Name:	vtrs_NumberOfDrugs
Namespace Prefix:	vtrs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Payments To Acquire Collaborative Agreement

+ References

No definition available.

+ Details

Name:	vtrs_PaymentsToAcquireCollaborativeAgreement
Namespace Prefix:	vtrs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=vtrs_MomentaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vtrs_TheravanceBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=vtrs_FKBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=vtrs_BiosimilarsBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=vtrs_RevanceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=vtrs_TheravanceBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vtrs_PeriodAxis=vtrs_FiscalYear2017Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SupplyCommitmentAxis=vtrs_GenericBiologicCompoundsCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=vtrs_RespiratorydeliveryplatformMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=vtrs_OtherCompaniesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and Licensing Agreements (Narrative) (Details) $ in Millions					3 Months Ended	12 Months Ended
	Feb. 27, 2019 USD ($)	Sep. 20, 2018 USD ($)	Jan. 30, 2015 USD ($)	Feb. 12, 2013 Product	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jan. 08, 2016 drugs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability							$ 199.7	$ 223.6	$ 250.7
Research and development							751.1	555.1	639.9
Proceeds from sale of assets and subsidiaries							96.7	20.0	$ 28.0
Momenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of drugs \| drugs										6
Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments							18.5
FKB
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments		$ 10.0
Upfront payments	$ 33.0	$ 25.0
Research and development	$ 23.3
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development							40.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Scenario, Forecast \| Biosimilars Business
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from sale of assets and subsidiaries					$ 2,000.0
Divestiture of Business, Deferred Cash Consideration.						$ 335.0
Divestiture Of Business, Percentage Ownership In Combined Company After Transaction					12.90%
Divestiture Of Business, Transition Services Agreement, Term						2 years
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Scenario, Forecast \| Biosimilars Business \| Convertible Preferred Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Equity consideration					$ 1,000.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Revance [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development								$ 30.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development							50.0
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments							351.0
Maximum \| Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments			$ 293.0
Fiscal Year 2017 \| Maximum \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments							18.0
Generic Biologic Compounds Collaboration [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Insulin Analog Products \| Product				3
Respiratory delivery platform [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability							177.8
Product rights and licenses \| Other companies
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Acquisition purchase price							10.0
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned							$ 25.0